Dimethylphenylpiperazinium
(Redirected from DMPP)
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H19N2 |
| Molar mass | 191.298 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Dimethylphenylpiperazinium (DMPP) is a nicotinic acetylcholine receptor agonist which is selective for the ganglionic subtype.[1] One of the earliest reports on the pharmacology of DMPP, describing it as a ganglion-stimulating, hypertensive agent, came from Graham Chen and his co-workers at Parke, Davis & Co. (Now Pfizer)[2]
See also
[edit]References
[edit]- ^ Prado WA, Segalla DK (August 2004). "Antinociceptive effects of bethanechol or dimethylphenylpiperazinium in models of phasic or incisional pain in rats". Brain Research. 1018 (2): 272–82. doi:10.1016/j.brainres.2004.05.085. PMID 15276888. S2CID 45145197.
- ^ Chen G, Portman R, Wickel A (November 1951). "Pharmacology of 1,1-dimethyl-4-phenylpiperazinium iodide, a ganglion stimulating agent". The Journal of Pharmacology and Experimental Therapeutics. 103 (3): 330–6. PMID 14898449.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |